Open-label, randomized, multicenter study with open-label extension to evaluate the pharmacokinetics and safety of the oral liquid solution and the dispersible formulation of topiramate as adjunctive therapy to concomitant antiepileptic treatment in children (1 to 23 months of age, both inclusive) suffering from Partial Refractory seizures
Latest Information Update: 27 Jul 2022
At a glance
- Drugs Topiramate (Primary) ; Topiramate (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors Janssen-Cilag
Most Recent Events
- 27 Jul 2022 New trial record